Research in Focus: Using Nitric Oxide to Tackle Cystic Fibrosis As part of #BiofilmWeek, we’re highlighting interesting and exciting biofilm research from across our network and partner research institutions by early career researchers and PhD students. We interviewed...
Revolutionising Healthcare Cystic fibrosis (CF) is a genetic disease that affects around 11,000 people in the UK, and over 160,000 globally. One of the most important bugs that causes this is Pseudomonas aeruginosa – a bacterium that is present everywhere but rarely...
Target Product Profiles for Diagnostics The Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate recently launched their diagnostic target product profiles (TPPs) detailing key characteristics of new tests needed to detect and manage lung infections in CF. A...
Phlegm-Like Material May Improve Modeling of Cystic Fibrosis Biofilms Scientists have engineered a living material resembling human phlegm, which will help them to better understand how a certain kind of infection develops on the lungs of patients with cystic...
CF AMR Syndicate: Lifting The Limits Of Cystic Fibrosis Antimicrobial Development Exploring the theme of ‘lifting the limits together’, this week (13-19 June) marks Cystic Fibrosis (CF) Week 2022. The event is a week-long opportunity to celebrate the courage and...
